DA 1241
Alternative Names: DA-1241Latest Information Update: 15 May 2025
At a glance
- Originator Dong-A ST
- Developer Dong-A ST; MetaVia
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 07 May 2025 Efficacy and clinical data from phase IIa trial in Non-alcoholic steatohepatitis released by MetaVia
- 20 Mar 2025 MetaVia anticipates scheduling end-of-phase II meeting with the US FDA, in the first half of 2025
- 28 Jan 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO)